Trial Profile
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Namilumab (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Acronyms RESOLVE-Lung
- Sponsors Kinevant Sciences GmbH
- 25 Apr 2024 According to a Roivant Sciences media release, topline results are expected by the end of calendar year 2024.
- 25 Apr 2024 Status changed from recruiting to active, no longer recruiting, according to a Roivant Sciences media release.
- 25 Apr 2024 According to a Roivant Sciences media release, company announced successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung).